Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Irene Williams-Elson"'
Autor:
Hye Sook Chon, Sokbom Kang, Jae K. Lee, Sachin M. Apte, Mian M. Shahzad, Irene Williams-Elson, Robert M. Wenham
Publikováno v:
BMC Cancer, Vol 17, Iss 1, Pp 1-8 (2017)
Abstract Background Ridaforolimus is a mammalian target of rapamycin inhibitor that has activity in solid tumors. Paclitaxel and carboplatin have broad antineoplastic activity in many cancers. This phase I trial was conducted to determine the safety
Externí odkaz:
https://doaj.org/article/1b109462c15a423c87e4159720107cd7
Autor:
William J. Fulp, Khaldoun Almhanna, Gregory M. Springett, David Shibata, Erin M. Siegel, Irene Williams-Elson, Amit Mahipal, Richard B. Kim
Publikováno v:
Invest New Drugs
Introduction Pasireotide (SOM230) is a somatostatin analog with high binding affinity for somatostatin receptors including sst1, 2, 3 and 5 and inhibit insulin like growth factor-1. Blocking of IGF-1 receptor (IGF-1R) in combination with cytotoxic ch
Autor:
Jae K. Lee, Mian M.K. Shahzad, Sachin M. Apte, Irene Williams-Elson, Sokbom Kang, Hye Sook Chon, Robert M. Wenham
Publikováno v:
BMC Cancer, Vol 17, Iss 1, Pp 1-8 (2017)
BMC Cancer
BMC Cancer
Ridaforolimus is a mammalian target of rapamycin inhibitor that has activity in solid tumors. Paclitaxel and carboplatin have broad antineoplastic activity in many cancers. This phase I trial was conducted to determine the safety profile, maximal tol
Autor:
Hye Sook Chon, Robert M. Wenham, Mian M.K. Shahzad, Sokbum Kang, Sachin M. Apte, Jae K. Lee, Irene Williams-Elson
Publikováno v:
Journal of Clinical Oncology. 34:e17031-e17031
e17031Background: Ridaforolimus (Rida) is a mammalian target of rapamycin (mTOR) inhibitor that has activity in solid tumors. Paclitaxel and carboplatin (PC) have broad antineoplastic activity in m...
Autor:
Nishi Kothari, Gregory M. Springett, Richard D. Kim, Kara Miller, Heloisa P. Soares, Amit Mahipal, Irene Williams-Elson, Danny T. Nguyen
Publikováno v:
Journal of Clinical Oncology. 34:TPS467-TPS467
TPS467 Background: The phosphatidylinositol 3-kinase (PI3K)/Akt/mTOR pathway which is aberrantly stimulated in many tumors has emerged as a potential target for anticancer therapy. Although several class I PI3K inhibitors are under development, there
Autor:
William J. Fulp, Erin M. Siegel, David Shibata, Jennifer Byer, Richard D. Kim, Amit Mahipal, Irene Williams-Elson, Khaldoun Almhanna
Publikováno v:
Journal of Clinical Oncology. 33:e15201-e15201
e15201 Background: Pasireotide (SOM230) is a somatostatin analog with high binding affinity for somatostatin receptors. It is hypothesized to induce apoptosis by decreasing insulin like growth fact...
Autor:
Hye Sook Chon, Patricia Lynn Judson, Sachin Apte, Ji-Hyun Lee, Irene Williams-Elson, Robert Michael Wenham
Publikováno v:
Journal of Clinical Oncology. 32:2614-2614
Autor:
Peter R. Rhode, Irene Williams-Elson, Julio Hajdenberg, Virginia Rizzo, Danny Landau, Hing C. Wong, Tessa Schutt, Liza Hernandez, Daniel A. Vaena, Bee-Yau Huang, Charles J. Rosser, Mayer Fishman, Pamela Zehr, Mohammed M. Milhem, Jeffrey S. Weber
Publikováno v:
Journal of Clinical Oncology. 30:e15010-e15010
e15010 Background: ALT-801 is a human IL-2/single-chain T-cell receptor fusion protein previously tested in a phase 1 in patients with advanced malignancy (Fishman 2011 CCR 17:7765) (CA097550). In various murine models, ALT-801 demonstrated potent ac